| Income Statement | 2025-09-30 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenues | 59,381 | 47,399 | ||
| Cost of revenue, excluding depreciation and amortization | 34,741 | - | ||
| Research and development | 1,784 | 2,352 | ||
| Cost of revenues | - | 25,778 | ||
| Clinical operations, net | 1,638 | 1,677 | ||
| Gross profit | - | 21,621 | ||
| Sales and marketing | 13,245 | 12,337 | ||
| General and administrative | 5,089 | 5,156 | ||
| Depreciation and amortization | 686 | - | ||
| Total costs and operating expenses | 57,183 | 21,522 | ||
| Income (loss) from operations | 2,198 | 99 | ||
| Financial income, net | -1,078 | -1,701 | ||
| Loss before taxes on income | 3,276 | 1,800 | ||
| Income tax expense (benefit) | 25 | -74 | ||
| Net income (loss) | 3,251 | 1,874 | ||
| Earnings per share - basic | 0.02 | 0.01 | ||
| Earnings per share - diluted | 0.02 | 0.01 | ||
| Weighted average number of shares outstanding, basic | 166,190,495 | 168,426,349 | ||
| Weighted average number of shares outstanding, diluted | 171,462,202 | 173,753,763 | ||
Talkspace, Inc. (TALK)
Talkspace, Inc. (TALK)